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Aims. To identify intracardiac hemostasis or fibrinolysis abnormalities, which are associatedwith atrial fibrillation (AF) and increase
the risk of thromboembolism. Patients and Methods. Patient group consisted of 24 patients with AF and control group included 14
individuals with other supraventricular tachycardia undergoing transcatheter radiofrequency ablation. Blood samples were drawn
from the femoral vein (FV), left atrium (LA), and left atrial appendage (LAA) before the ablation procedure. Fibrinogen, factor
VIII (FVIII) and factor XIII activity, von Willebrand factor (VWF) antigen, thrombin-antithrombin (TAT) complex, quantitative
fibrin monomer (FM), plasminogen, 𝛼
2
-plasmin inhibitor, plasmin-𝛼
2
-antiplasmin (PAP) complex, PAI-1 activity, and D-dimer
were measured from all samples. Results. Levels of FVIII and VWF were significantly elevated in the FV and LA of AF patients as
compared to controls. TAT complex, FM, PAP complex, and D-dimer levels were significantly elevated in the LA as compared
to FV samples in case of both groups, indicating a temporary thrombotic risk associated with the catheterization procedure.
Conclusions. None of the investigated hemostasis or fibrinolysis parameters showed significant intracardiac alterations in AF
patients as compared to non-AF controls. AF patients have elevated FVIII and VWF levels, most likely due to endothelial damage,
presenting at both intracardiac and systemic level.
1. Introduction
Atrial fibrillation (AF) is the most common sustained car-
diac arrhythmia associated with a high risk of mortality
and morbidity from stroke and thromboembolism [1]. The
precise mechanism by which AF causes thromboembolism
and subsequent cerebrovascular events is yet to be fully
elucidated. It is widely recognized that thromboembolism in
AF is associated with a combination of pathophysiological
mechanisms, which fulfill the requirement of Virchow’s triad
for thrombogenesis: stasis, abnormal change in the vessel wall
and pathological imbalance of hemostasis, and fibrinolysis
[2]. Although several risk factors (age, hypertension, diabetes
mellitus, etc.) predispose to stroke in patients with AF, it
has been controversial whether the arrhythmia itself leads
to hypercoagulability [3–5]. Nonetheless, it is a well-known
fact that anticoagulation therapy reduces the risk of ischemic
stroke in AF patients by two-thirds [6]. There are a number
of reports available on the activation of coagulation cascade
in AF, but fibrinolytic activity in AF patients has been less
studied [7–10]. Most studies have focused on the relation
of AF-associated thromboembolism with various endothelial
damage markers, prothrombotic or inflammatory factors,
and plasma markers of platelet activation [4, 8, 11, 12]. It
has been shown that AF is associated with increased levels
of prothrombin fragments 1 + 2 (F1 + 2) and thrombin-
antithrombin (TAT) complex, elevated plasma fibrinogen
levels alongside with endothelial markers of soluble throm-
bomodulin, and vonWillebrand factor (VWF) [2, 13–16].The
role of fibrinolysis in the pathomechanism of AF-associated
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thromboembolism has been much less studied and contro-
versial findings have been published. AF has been associated
with hypofibrinolysis due to increased levels of plasminogen
activator inhibitor type 1 (PAI-1) [17], although in other
studies hyperfibrinolysis with elevated tissue plasminogen
activator (t-PA) [18–22] and plasmin-𝛼
2
-antiplasmin (PAP)
complex levels were found [23]. Impaired fibrinolysis due
to unfavorably altered fibrin clot properties has been also
described in AF patients [9]. These reports present data on
coagulation and fibrinolytic markers measured in peripheral
samples; however, the prothrombotic effects of AF are most
likely to develop on a local, cardiac level andmay notmanifest
in the peripheral circulation. Recent studies suggest that there
is a difference between the left atrium (LA) and the systemic
circulation in AF patients and the thrombogenic pathology is
more likely to be restricted to the heart [24, 25]. However,
most possibly due to the difficulty of intracardiac blood
sampling, in the last decade only few studies, involving a rel-
atively small number of patients, investigated the hemostasis
or fibrinolytic system in samples obtained from the LA of
patients with AF [11, 26–28]. Unfortunately, these few studies
using LA samples published so far examined only a subset
of coagulation markers and even less is known about the
fibrinolytic system in this respect. As to our knowledge, the
levels of blood coagulation factor XIII (FXIII) or 𝛼
2
-plasmin
inhibitor (𝛼
2
-PI), although key regulators of fibrinolysis, have
not been studied from intracardiac samples as yet. Moreover,
in most cases, results obtained from the intracardiac samples
of AF patients were not compared to age and sex-matched
non-AF intracardiac samples [11, 26]. As the intervention of
intracardiac blood sampling is an invasive procedure with a
potential effect on the hemostasis system, it is essential to
compare results to a population undergoing the same inter-
vention, but not having AF. Furthermore, in some studies
patients received unfractionated heparin prior intracardiac
blood sampling, which of course has a major impact on
the hemostasis system and limits the number of parameters
that could be determined from these samples [26]. The
investigation of blood samples obtained from the left atrial
appendage (LAA) of AF patients is also intriguing, as it has
been suggested that the LAA is the most thrombogenic part
of the heart inAF, being themost frequent location of embolic
thrombi [29]. Nevertheless, available data on coagulation or
fibrinolysis markers in LAA samples of AF patients are a
rarity.
In this study we aimed to identify local hemostasis and
fibrinolysis abnormalities, which are associated with AF and
increase the risk of thromboembolism. Intracardiac blood
samples taken from the LA and LAA of AF patients and
non-AF controls were tested for a comprehensive set of
hemostasis and fibrinolytic factors in order to assess AF-
associated alterations.
2. Methods
2.1. Study Population. Consecutive patients undergoing radi-
ofrequency ablation for symptomatic paroxysmal or persis-
tent AF (AF group) as well as age- and sex-matched patients
with any arrhythmia other than AF requiring left atrial access
(non-AF control group) were enrolled in the study. Patients
were enrolled between 2013 October and 2015 December. All
AF patients were undergoing pulmonary vein isolation (PVI)
with phased radiofrequency (RF) or cryoballoon ablation
procedure. Non-AF controls were undergoing routine RF
ablation of a left atrial substrate (mostly a left-sided accessory
atrioventricular pathway).
Inclusion criteria for the AF group were the following:
age 18–75 years, documented, symptomatic paroxysmal or
persistent AF, failure of at least one antiarrhythmic drug,
and patient being willing to sign a written informed consent.
Inclusion criteria for the control group were age 18–75
years, documented non-AF arrhythmia including one of the
following: left atrial tachycardia, paroxysmal supraventricu-
lar tachycardia (orthodromic or antidromic), or FBI (fast,
broad, and irregular) tachycardia due to a left-sided accessory
pathway, preexcitation on the 12-lead electrocardiogram in
an asymptomatic individual in whom the electrophysiology
study revealed a left-sided accessory pathway potentially
resulting in significant arrhythmia based on its conduc-
tion properties, and patient being willing to sign a written
informed consent. Exclusion criteria for the patient and
control groups were previous heart surgery, valvular heart
disease, left ventricular ejection fraction (LVEF) ≤ 30%,
heart failure of New York Heart Association functional
classification (NYHA) class III or IV, documented carotid
stenosis, history of ischemic stroke or TIA, prior cardiac
surgery, unstable angina or myocardial infarction within
the last 3 months, severe chronic obstructive pulmonary
disease, known bleeding or thrombotic disorders, acute
inflammation, contraindication to oral anticoagulation or to
diffusion weighted magnetic resonance imaging (DWMRI),
and pregnancy. Additional exclusion criteria for the patient
group were long-standing persistent AF, reversible cause of
AF (e.g., hyperthyroidism), and presence of AF thrombus.
Risk factors for stroke (hypertension, diabetes mellitus,
smoking, BMI, etc.) together with the list of current med-
ications were assessed before the enrollment of patients.
The CHADS
2
score (congestive heart failure, hyperten-
sion, age ≥ 75 years, diabetes mellitus, and stroke/transient
ischemic attack), CHA
2
DS
2
-VASC score (congestive heart
failure, hypertension, age ≥ 75 years, diabetes mellitus,
stroke/transient ischemic attack/thromboembolism, vascular
disease (prior myocardial infarction, peripheral vascular dis-
ease, or aortic atherosclerosis), age (65–74 years), and sex cat-
egory (female)), and EHRA score (European Heart Rhythm
Association score) [30] were recorded for every AF patient.
The study design was in accordance with the guiding
principles of the Declaration of Helsinki, and was approved
by the Institutional Ethics Committee of the University
of Debrecen and the Ethics Committee of the National
Medical ResearchCouncil (ETT-TUKEB). All patients signed
a written informed consent form prior to inclusion.
2.2. Electrophysiology Procedure and Blood Drawing. Patients
were hospitalized 1 or 2 days before the procedure. All
medications with a potential effect on coagulation or platelet
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activity were discontinued for a period of at least three half-
lives (or a period needed for reaching complete decay of their
action) before the procedure. Transesophageal echocardiog-
raphy was carried out within 24 h prior to the procedure in
order to rule out the presence of a cardiac thrombus in all
AF patients. All procedures were carried out under conscious
sedation, using midazolam and fentanyl. The ablation proce-
dures were performed as described previously [31, 32]. Blood
samples were taken before the ablation procedures from
multiple sites: (1) peripheral femoral venous (FV) sheath, (2)
left atrial (LA) sheath, and (3) left atrial appendage (LAA)
sheath. Intracardiac blood samples were collected before the
administration of unfractionated heparin.
Briefly, three punctures of the right femoral vein were
performed using the Seldinger technique and introducers
with side arms were placed in the vein. Forty-five ml blood
sample was drawn through the side arm of a short introducer
immediately after access to the vein, from which the first
5ml of blood was discarded in order to exclude intrasheath
hemostasis activation (FV sample). Blood samples were
collected into vacutainer tubes (tubes anticoagulatedwithK
3
-
EDTA for complete blood count, tubes containing 0.109M
sodium citrate and CTAD (buffered citrate, theophylline,
adenosine, and dipyridamole)) for hemostasis and fibrinoly-
sis tests (Becton Dickinson, Franklin Lakes, NJ). After blood
drawing, a decapolar catheter and an intracardiac echo (ICE)
catheter were advanced from the femoral vein and positioned
in the coronary sinus and in the right atrium, respectively. A
single ICE-guided transseptal puncture was performed using
a Mullins transseptal sheath and a Brockenborough needle
(Medtronic, Kirkland, QC, Canada) under fluoroscopic and
ICE guidance using standard technique. After crossing the
septum, the dilator of the Mullins sheath was removed and
45ml blood sample was drawn from the LA, from which
the first 5ml of blood was discarded (LA sample). LA blood
samples were collected into vacutainer tubes as described
above. After the blood drawing of LA samples, the LAA was
accessed by using a 5 F pigtail catheter (Medtronic, Kirkland,
QC, Canada) under fluoroscopy and ICE control. A blood
sample of 45ml was taken from the LAA, of which, again, the
first 5ml was discarded (LAA sample). LAA blood samples
were collected into vacutainer tubes as described above.
Immediately after blood samplings, 150 IU/kg body weight
i.v. heparin was administered and ablations were performed
according to standard protocols.
2.3. Laboratory Investigations. Blood samples anticoagulated
with K3-EDTA were immediately tested for complete blood
count. Blood samples anticoagulated with citrate or CTAD
were centrifuged twice at 1500 g at room temperature for
20min and plasma samples were stored at −70∘C until
further analysis. The measurement of plasminogen activator
inhibitor-1 (PAI-1) activity was performed from plasma sam-
ples anticoagulated with CTAD; besides this measurement,
all hemostasis and fibrinolysis tests were performed using
citrated plasma. Hemostasis and fibrinolysis tests were per-
formed from all sample types (FV, LA, and LAA samples).
Screening tests of hemostasis (prothrombin time, activated
partial thromboplastin time, and thrombin time) were per-
formed using routine methods (Siemens Healthcare Diag-
nostic Products, Marburg, Germany). Fibrinogen concentra-
tions were measured by the Clauss method. Commercially
available ELISA tests were used to determine PAI-1 activity
(Technozym PAI-1 Actibind, Technoclone, Vienna, Aus-
tria), plasmin-𝛼
2
-antiplasmin (PAP) complex (Technozym
PAP complex ELISA kit, Technoclone, Vienna, Austria),
and thrombin-antithrombin (TAT) complex (Enzygnost TAT
micro, Siemens Healthcare Diagnostic Products, Marburg,
Germany). Factor VIII (FVIII) activity using a chromogenic
assay, von Willebrand factor (VWF) antigen level, 𝛼
2
-
plasmin inhibitor (𝛼
2
-PI) activity, plasminogen activity and
D-dimer levels were measured on a BCS coagulometer by
standard methods (Siemens Healthcare Diagnostic Products,
Marburg, Germany). Plasma levels of FXIII activity were
determined by ammonia release assay [33] using a commer-
cially available reagent kit (REA-chrom FXIII kit, Reanal-
ker, Budapest, Hungary). Soluble fibrinmonomer levels (FM)
weremeasured using the Liatest FMassay (Diagnostica Stago,
Asnie`res, France).
High sensitivity C-reactive protein (CRP) and a com-
prehensive lipid profile including total cholesterol, low-den-
sity lipoprotein (LDL) cholesterol, high-density lipoprotein
(HDL) cholesterol, and triglyceride levels were measured
from antecubital vein blood samples of all patients upon
hospital admission by routine methods (Roche Diagnostics,
Mannheim, Germany).
2.4. Statistical Analysis. All data were analyzed using the
GraphPad Prism Software version 5.0 (La Jolla, CA) and the
Statistical Package for Social Sciences (SPSS, Release 22.0,
Chicago, IL). Normality of the data was evaluated by the
D’Agostino and Pearson omnibus normality test. A paired t-
test or Wilcoxon matched pairs rank-sum test was applied
for comparing results obtained from intracardiac and FV
samples. In case of two-group analyses between AF patients
and controls, unpaired t-test or in case of nonparametric
data Mann–Whitney 𝑈 test was used. ANOVA or Kruskal-
Wallis test was applied for multiple comparisons. Pearson’s
or Spearman’s correlation coefficient was used to determine
the strength of correlation between variables. Differences
between categorical variables were assessed by the Fisher’s
exact test. 𝑝 < 0.05 was considered statistically significant.
3. Results
3.1. Baseline Characteristics of AF Patients and Non-AF Con-
trols. Clinical characteristics of the AF patient group and
control group are shown in Table 1. In total 32 AF patients
and 18 controls were enrolled in the study. Unfortunately,
8 AF patients and 4 controls had to be excluded from the
study population due to technical problems arising during the
intracardiac blood drawing procedure (clot formation in the
sample during the blood drawing procedure, clot formation
on the sheath requiring instant heparin administration, etc.).
In case of 12 AF patients and 8 non-AF controls an LAA
sample was not possible to obtain due to technical/anatomic
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Table 1: Characteristics of atrial fibrillation (AF) patients and controls.
Variables AF group non-AF control group 𝑝 value
Number of patients after exclusions 24 14
Age (years) 56.45 (47.43–59.80) 50.60 (32.80–56.10) 0.061
Male, 𝑛 (%) 15 (62.50) 10 (71.43) 0.728
BMI (kg/m2) 29.43 ± 5.52 26.10 ± 4.75 0.068
Cerebrovascular risk factors, 𝑛 (%)
Arterial hypertension 13 (54.17) 8 (57.14) 1.000
Hypercholesterolemia 19 (79.17) 8 (57.14) 0.266
Current smoking 2 (8.33) 6 (42.86) 0.013
Diabetes mellitus 2 (8.33) 0 —
Previous myocardial infarction, 𝑛 (%) 0 0 —
Previous ischemic stroke, 𝑛 (%) 0 0 —
Heart failure, 𝑛 (%) 1 (4.17) 0 —
Left atrium size (mm) 39.71 ± 4.82 36.55 ± 4.80 0.081
AF period during procedure, 𝑛 (%) 2 (8,33) — —
CHADS
2
score, 𝑛 (%)
0 10 (41.67) n.a. —
1 10 (41.67) n.a. —
2 4 (16.67) n.a. —
CHA
2
DS
2
-VASC score, 𝑛 (%)
0 6 (25.00) n.a. —
1 9 (37.50) n.a. —
2 5 (20.83) n.a. —
3 3 (12.50) n.a. —
4 1 (4.17) n.a. —
EHRA score, 𝑛 (%)
1 3 (12.50) n.a. —
2 1 (4.17) n.a. —
3 16 (66.67) n.a. —
4 4 (16.67) n.a. —
Medication, 𝑛 (%)
Statin 6 (25.00) 2 (14.29) 0.684
ACEI 8 (33.33) 6 (42.86) 0.729
Beta-blocker 17 (70.83) 9 (64.29) 0.728
Laboratory parameters
C-reactive protein (mg/L) 1.50 (0.60–2.75) 1.10 (0.13–2.05) 0.281
Total cholesterol (mmol/L) 5.30 ± 1.16 4.69 ± 1.09 0.122
LDL cholesterol (mmol/L) 3.42 ± 0.98 2.79 ± 0.91 0.061
HDL cholesterol (mmol/L) 1.44 (0.32) 1.46 ± 0.42 0.812
Triglyceride (mmol/L) 1.80 (1.23–2.18) 1.4 (0.75–1.95) 0.208
Zero blood group, 𝑛 (%) 7 (29.17) 2 (14.29) 0.446
Continuous variables are expressed asmean ± SD ormedian (interquartile range). Categorical variables are indicated as number (percentage), unless otherwise
stated. AF: atrial fibrillation; 𝑛: number; IQR: interquartile range; SD: standard deviation; n.a.: nonapplicable; BMI: bodymass index; CHADS2 score: congestive
heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke/transient ischemic attack; CHA2DS2-VASC score: congestive heart failure, hypertension,
age≥ 75 years, diabetesmellitus, stroke/transient ischemic attack/thromboembolism, vascular disease (priormyocardial infarction, peripheral vascular disease,
or aortic atherosclerosis), age (65–74 years), sex category (female); EHRA score: European Heart Rhythm Association score; ACEI: angiotensin converting
enzyme inhibitor; LDL cholesterol: low density lipoprotein cholesterol; HDL cholesterol: high density lipoprotein cholesterol.
difficulties. The final numbers of AF patients and non-AF
controls included in the study were 24 and 14, respectively
(Table 1). No significant differences were observed between
the AF patients and non-AF controls regarding BMI and
cerebrovascular risk factors except for smoking, which was
more frequent in controls. Only two patients experienced
paroxysmal AF periods during the procedure. Most AF
patients had low or moderate risk for stroke according to
the CHADS
2
and CHA
2
DS
2
-VASC score. A similar fraction
of AF patients and non-AF controls received statins and
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Figure 1: Levels of various coagulation factors in patients with atrial fibrillation (AF) and non-AF controls. Box and whisker plots indicate
median, interquartile range, and total range. Dashed lines indicate upper and lower limits of reference interval. FVIII: factor VIII; VWF: von
Willebrand factor; FXIII: factor XIII; FV: femoral vein; LA: left atrium; LAA: left atrial appendage. ∗𝑝 < 0.05; ∗∗𝑝 < 0.01.
antihypertensive drugs. CRP levels and lipid parameters,
measured from peripheral venous blood samples, did not
differ significantly between AF patients and non-AF controls.
3.2. Intracardiac Levels of Hemostasis Factors in AF Patients
and Non-AF Controls. FVIII activity and VWF antigen levels
were significantly higher in theAF patient group as compared
to the control group in the samples obtained from the FV and
from the LA (Figure 1). LAA levels of both proteins showed a
marked elevation in AF patients as well; however, very likely
due to the lower number of LAA samples, results were only
borderline significance. Elevated levels were not due to acute
phase reaction as CRP levels of all individuals were in the
normal range. In case of AF patients, median values of VWF
antigen levels were above the upper limit of the reference
interval in all sample types (171% (IQR: 129.4–195.1%), 176.7%
(IQR: 129.3–192.7%), and 164% (IQR: 114.8–189.8%) for FV,
LA, and LAA sample types, resp.). The observed differences
between patients and controls remained significant after
adjustments for AB0 blood type in the statistical model. No
local differences were found in the FVIII and VWF levels
of intracardiac samples as compared to the FV samples in
either group. FVIII and VWF levels showed good correlation
in AF patients (Spearman 𝑟 = 0.808, 95% CI: 0.691–0.884,
𝑝 < 0.0001) as well as in non-AF controls (Pearson 𝑟 = 0.737,
95% CI: 0.502–0.871, 𝑝 < 0.0001), suggesting that they are in
a complex form. No considerable differences were seen in the
correlation of FVIII and VWF levels with respect to sampling
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Figure 2: Levels of quantitative fibrin monomer and thrombin-antithrombin (TAT) complex in patients with atrial fibrillation (AF) and
non-AF controls. Box and whisker plots indicate median, interquartile range, and total range. Dashed lines indicate upper limit of reference
interval. FV: femoral vein; LA: left atrium; LAA: left atrial appendage. ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.001.
sites (data not shown). No significant differences were found
between sample types and patient groups in case of FXIII
activity and fibrinogen levels.
3.3. Intracardiac Levels of Coagulation Activation Markers
in AF Patients and Non-AF Controls. Median values of
soluble FM and TAT complex levels exceeded the upper
limit of reference interval in the FV samples of AF patients
(18.16 𝜇g/mL (IQR: 5.83–33.91 𝜇g/mL) and 15.17 𝜇g/L (IQR:
6.96–22.83𝜇g/L) for FMandTAT, resp.) and non-AF controls
(23.05 𝜇g/mL (IQR: 9.55–51.41𝜇g/mL) and 16.36 𝜇g/L (IQR:
9.84–28.59𝜇g/L) for FM and TAT, resp.) (Figures 2(a) and
2(b)). Moreover, both parameters were significantly elevated
in the samples obtained from the LA as compared to the
FV samples in case of both groups, suggesting that that the
observed differences are not AF-specific and most probably
the catheterization procedure itself has a major effect on the
results. FM levels showed a decrease in the LAA samples as
compared to the LA samples; this decrease was significant
in case of the patients (𝑝 < 0.001, Wilcoxon matched pairs
rank-sum test) (Figure 2(a)). TAT complex levels were also
significantly lower in the LAA samples versus LA samples of
AF patients (𝑝 < 0.01, Wilcoxon matched pairs rank-sum
test), while such significant association was not observed in
case of the non-AF control patients (Figure 2(b)). TAT com-
plex levels were significantly increased in the LAA samples
of both AF patients and non-AF controls as compared to the
FV samples. Surprisingly, a marginal but significant elevation
was observed in the TAT complex levels of the LA samples of
non-AF controls versus AF patients (𝑝 < 0.05).
3.4. Intracardiac Parameters of Fibrinolysis in AF Patients
and Non-AF Controls. Plasminogen activity, 𝛼
2
-PI activity,
and PAI-1 activity levels showed no difference between AF
patients as compared to non-AF controls (Figures 3(a), 3(b),
and 3(d)). In general, no difference was observed between
the intracardiac and peripheral levels of these parameters,
except for a small, but significant reduction of plasminogen
level in the LAA versus FV sample of the AF patients
(Figure 1(a)). PAP complex and D-dimer levels were signif-
icantly increased in the LA samples of both AF patients and
non-AF controls as compared to the respective FV samples
(Figures 3(c) and 3(d)), suggesting that the activation of
the fibrinolytic system took place during the transcatheter
procedure in both groups. In fact, approximately half of
the AF patients and non-AF controls had D-dimer levels
exceeding the cut-off value in the LA sample, while me-
dian values of D-dimer were well below the cut-off in the
FV samples (0.26mgFEU/L (IQR: 0.17–0.48mgFEU/L) and
0.30mgFEU/L (IQR: 0.18–0.48mgFEU/L) in AF patients and
controls, resp.) (Figure 3(d)).
4. Discussion
Although it is a general belief that in AF the intracardiac
milieu is more thrombogenic than the peripheral blood,
supporting pieces of evidence derived from measurements
using intracardiac blood samples are scarce. In this study, we
investigated the levels of a comprehensive list of hemostasis
and fibrinolysis markers from intracardiac blood samples of
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Figure 3: Levels of various fibrinolytic markers in patients with atrial fibrillation (AF) and in non-AF controls. Box and whisker plots indicate
median, interquartile range, and total range. Dashed lines indicate upper and lower limits of reference interval or diagnostic cut-off levels.
PAP complex: plasmin-𝛼
2
-antiplasmin complex; PAI-1: plasminogen activator inhibitor type 1, FV: femoral vein; LA: left atrium; LAA: left
atrial appendage; ∗𝑝 < 0.05; ∗∗𝑝 < 0.01.
AF patients and non-AF controls and failed to detect signif-
icant AF-specific alterations of hemostasis or fibrinolysis in
intracardiac blood samples. It is to be noted, however, that
only two patients experienced paroxysmal AF periods during
the procedure, which means that most patients were on sinus
rhythm during blood sampling. Our results suggest that as
compared to peripheral samples, paroxysmal/persistent AF
patients have no significant alterations in the intracardiac lev-
els of the investigated hemostasis and fibrinolytic parameters,
at least when they are not experiencing AF periods.
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Although significant local differences were observed
for certain coagulation activation and fibrinolytic markers
(namely, for FM, TAT complex, PAP complex, and D-dimer
levels) in the intracardiac samples as compared to the FV
samples, the same differences were found in non-AF control
individuals. Moreover, in the LAA sample of both groups,
a general tendency of decrease was observed in the level of
most investigated markers as compared to LA samples. In
earlier studies, in which non-AF control population was not
investigated, these differences were attributed to AF patho-
physiology [26]. However, our results imply that changes in
the level of thesemarkers are not specific for AF and are likely
to be attributed to the invasive nature of the catheterization
procedure, including transseptal puncture and tissue damage.
Among all investigated hemostasis and fibrinolysis
parameters, only the elevation of FVIII and VWF levels was
found to be AF-associated in our study. Interestingly, FVIII
andVWF levels were significantly elevated in both peripheral
and intracardiac blood samples of AF patients as compared to
controls. Elevation of VWF levels was particularly consider-
able in the AF patient group as the medians of VWF levels
were at the upper limit of the reference interval in all sample
types. Although the levels of VWF in AF patients have been
studied earlier using peripheral samples, the relationship
between intracardiac and peripheral VWF levels has been
obscure. An elevation of FVIII [18, 34] and VWF [35–
38] has been described earlier in the peripheral samples
AF patients and it has been proposed to be attributed to
endothelial damage. Moreover, elevated levels of VWF have
been associatedwith increased stroke risk and poor prognosis
[36, 39, 40]. Only few papers enrolling a limited number of
patients have investigated the levels of VWF in AF patients
from both intracardiac and peripheral blood samples, but in
these studies FVIII levels were not determined [27, 41]. In line
with our findings, in these earlier reports it was found that
VWF levels were similar in the intracardiac samples and in
samples obtained from the peripheral sampling site. In our
study FVIII and VWF levels showed good correlation in all
sample types, suggesting that they were in complexed form.
As both proteins are stored in the Weiber-Palade bodies of
the endothelium [42], these results imply that the elevation
of VWF and FVIII levels are the consequence of endothelial
damage not necessarily restricted to the LA. It has to be noted
that in the LAA of patients a similar tendency of FVIII and
VWFelevationwas observed as in case of FV andLA samples,
but most likely due to the limited number of LAA samples,
differences were not proved to be significant between patients
and controls for this sample type.
Despite the important role of fibrinolytic system in
preventing intravascular thrombosis, previous studies have
paid little attention to the investigation of fibrinolytic abnor-
malities associated with AF [8]. Moreover, little is known
about the levels of important regulators of fibrinolysis in
intracardiac samples in AF. Here we assessed a series of
fibrinolytic markers from both peripheral and intracardiac
blood samples of AF patients and non-AF controls. Besides
a small, but significant decrease in the levels of plasminogen
in the LAA samples of AF patients as compared to the FV
samples, no significant differences were observed between
AF patients and non-AF controls and among sample types
concerning FXIII activity, 𝛼
2
-plasmin inhibitor, PAI-1 activ-
ity, and plasminogen activity measurements. There was no
difference between PAP complex and D-dimer levels in AF
patients and non-AF controls as well. These finding suggests
that the investigated components of the fibrinolytic system
are mostly unaltered in AF.
5. Limitations
Our study has some limitations. First, the number of patients
enrolled in the study was limited, which was obviously
due to the highly invasive nature of the blood sampling,
during which technical difficulties were often encountered.
We would like to highlight, however, that the number of
patients enrolled in our study is still more than the average
number of patients undergoing this kind of blood sampling
as published so far. Moreover, in our study a non-AF control
patient group was also enrolled, which is often missing
from earlier studies. Despite the particularly difficult and
potentially risky technique of LAA sampling, a considerable
number of patients were sampled from the LAA as well,
which is a rarity in the literature as yet. Based on our findings
larger studies are warranted to corroborate our observations.
Second, most patients enrolled in the study had low or
moderate stroke risk according to the CHADS2 or CHA2DS2-
VASC score, which limits the extrapolation of our findings
to the general AF patient population. It has to be noted,
however, that the stroke risk of our patient population reflects
the current practice of most ablation centers, which offer
ablation for younger patients with mostly paroxysmal AF,
structurally normal heart, and no significant comorbidity
[43]. In addition, the necessity and safety of the discontinua-
tion of anticoagulation preablation (which was a requirement
in our study in order to carry out certain measurements) are
only evident in low-risk patients [44].
Third, only 2 patients experienced a paroxysmal AF
period during the catheterization and blood drawing pro-
cedure. Naturally, more patients having AF period during
sampling could have supplemented our results with a further
interesting aspect.
6. Conclusion
AF patients have elevated FVIII and VWF levels, most
likely due to endothelial damage, which is present in the
intracardiac and peripheral environment as well. Intracardiac
activation of hemostasis and fibrinolysis was demonstrated in
AF patients and in non-AF controls to a similar extent, indi-
cating that this might be a consequence of the catheterization
procedure itself rather than a footprint of AF pathophysiol-
ogy.
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